Keyphrases
Second-line Treatment
100%
Graft-versus-host Disease (GvHD)
100%
Infliximab
100%
Survival Prediction
100%
Treatment Failure
50%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Survival Probability
25%
Low-risk Group
25%
Composite Endpoint
25%
Non-responders
25%
Alternative Therapy
25%
Proposed Guidelines
25%
Immunosuppressive Drugs
25%
Overall Survival
25%
Consecutive Patients
25%
Immunosuppression
25%
High-risk Population
25%
Failure Cause
25%
Immunology and Microbiology
Infliximab
100%
Acute Graft Versus Host Disease
100%
Immunosuppression
20%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Survival Rate
20%
Immunosuppressive Drug
20%
High Risk Population
20%
Low Risk Population
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
100%
Infliximab
100%
Immunosuppressive Agent
20%
Survival Rate
20%
Neuroscience
Infliximab
100%
Hematopoietic Cell
33%
Immunosuppressive Drug
33%
Immunosuppression
33%